SCHEMBL5457872

SCHEMBL5457872

CCN(CCOc1cc[c]cc1)C(N)=O

nearest known ligand 0.42

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MMP2 P08253 2/20 0.42
NPC1 O15118 2/20 0.39
LMNA P02545 1/20 0.39
ALOX15 P16050 1/20 0.39
TSHR P16473 1/20 0.39
MAPK1 P28482 1/20 0.39
HSD17B10 Q99714 1/20 0.39
EBP Q15125 1/20 0.38
SIGMAR1 Q99720 1/20 0.38
MEN1 O00255 1/20 0.38
KMT2A Q03164 1/20 0.38
MCHR1 Q99705 2/20 0.36
RAB9A P51151 1/20 0.36
MAOB P27338 1/20 0.36
MMP3 P08254 1/20 0.36
KCNH2 Q12809 1/20 0.36
PARP10 Q53GL7 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4760882 0.84 NPC1 (0.54) NPC1LMNAALOX15TSHRMAPK1
SCHEMBL3120414 0.78 NPC1 (0.50) NPC1LMNAALOX15TSHRMAPK1
SCHEMBL3123222 0.77 NPC1 (0.59) NPC1LMNAALOX15TSHRMAPK1
SCHEMBL187890 0.75 EBP (0.57) TSHREBPSIGMAR1MEN1KMT2A
SCHEMBL8749756 0.74 NPC1 (0.62) NPC1TSHRRAB9A
SCHEMBL4717191 0.74 PARP10 (0.42) MMP2HSD17B10MEN1KMT2APARP10
SCHEMBL3169239 0.73 MMP2 (0.45) MMP2RAB9AMMP3
SCHEMBL1148129 0.72 L3MBTL1 (0.42) MMP2MMP3PARP10
SCHEMBL6993806 0.72 L3MBTL1 (0.43) PARP10
SCHEMBL158044 0.71 HRH3 (0.58)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070123561-A1 Preparation of 1,7-disubstituted azabensimidazoles as kinase inhibitors LEE DENNIS 2007-05-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070123561-A1 Preparation of 1,7-disubstituted azabensimidazoles as kinase inhibitors TNK2, CDC42BPB, CDC42BPA MMP2 2362/4885NPC1 4071/4885LMNA 3322/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.